The IND of APL-1202 and BeiGene's combined neoadjuvant treatment of MIBC is approved by CDE

Shanghai, October 13, 2021/PRNewswire/ - Yahong Pharmaceutical announced today that its oral drug APL-1202 and BeiGene Baizean® (tislelizumab) combined with neoadjuvant treatment of muscle invasion The New Drug Clinical Research Application (IND) for bladder cancer (MIBC) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China

The study is an open-ended, multi-center international phase I/II clinical study.

APL-1202 is an oral reversible MetAP2 inhibitor with anti-angiogenesis, anti-tumor activity and regulation of tumor immune microenvironment

According to the 2020 Chinese Society of Clinical Oncology (CSCO) Urothelial Carcinoma Diagnosis and Treatment Guidelines, for patients who can tolerate radical bladder cancer surgery, radical cystectomy (Radical Cystectomy) is performed after neoadjuvant chemotherapy if they are tolerant of cisplatin.

Dr.

About Yahong Medicine

Established in March 2010, Yahong Pharmaceutical is a global innovative drug company focusing on genitourinary system tumors and other major diseases

The company insists on taking innovative technologies and products as its core driving force, and by building its own R&D platform and core technology, it deeply explores the mechanism of drug action, and efficiently screens and evaluates drug candidates

At the same time, through independent research and development and strategic cooperation, Yahong has carried out in-depth layout of product pipelines around genitourinary system diseases, paid close attention to the technological frontiers and treatment development trends in this field, insight and mining unmet clinical needs, and forward-looking products Planning and life cycle management, to create a superior product portfolio from disease diagnosis to treatment, so as to benefit more Chinese and global patients

Source: Asieris